158 related articles for article (PubMed ID: 19541791)
1. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.
Montero AJ; Diaz-Montero CM; Millikan RE; Liu J; Do KA; Hodges S; Jonasch E; McIntyre BW; Hwu P; Tannir N
Ann Oncol; 2009 Oct; 20(10):1682-7. PubMed ID: 19541791
[TBL] [Abstract][Full Text] [Related]
2. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
[TBL] [Abstract][Full Text] [Related]
3. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
[TBL] [Abstract][Full Text] [Related]
4. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
5. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
[TBL] [Abstract][Full Text] [Related]
7. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
Kwon KA; Kim SH; Oh SY; Lee S; Han JY; Kim KH; Goh RY; Choi HJ; Park KJ; Roh MS; Kim HJ; Kwon HC; Lee JH
BMC Cancer; 2010 May; 10():203. PubMed ID: 20465852
[TBL] [Abstract][Full Text] [Related]
9. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
10. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
Tannir NM; Cohen L; Wang X; Thall P; Mathew PF; Jonasch E; Siefker-Radtke A; Pagliaro LC; Ng CS; Logothetis C
Cancer; 2006 Nov; 107(9):2254-61. PubMed ID: 17029276
[TBL] [Abstract][Full Text] [Related]
11. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
12. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
13. Association between clinical features and course of systemic sclerosis and serum interleukin-8, vascular endothelial growth factor, basic fibroblast growth factor, and interferon alpha.
Kosałka-Węgiel J; Lichołai S; Dziedzina S; Milewski M; Kuszmiersz P; Korona A; Korkosz M; Gąsior J; Matyja-Bednarczyk A; Kwiatkowska H; Siwiec-Koźlik A; Sydor W; Wilańska J; Zaręba L; Pociej-Marciak W; Dropiński J; Sanak M; Musiał J; Bazan-Socha S
Adv Clin Exp Med; 2024 Apr; 33(4):369-377. PubMed ID: 37540156
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
15. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma.
Beecken WD; Bentas W; Glienke W; Linneweber J; Jonas D; Binder J; Kramer W
Eur Urol; 2002 Oct; 42(4):364-9. PubMed ID: 12361902
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
[TBL] [Abstract][Full Text] [Related]
17. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.
Ock CY; Nam AR; Lee J; Bang JH; Lee KH; Han SW; Kim TY; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Mar; 20(2):254-262. PubMed ID: 27147244
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
20. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
